Immunostimulatory activity and structure-activity relationship of epimedin B from Epimedium brevicornu Maxim.
Open Access
- 31 October 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1015846
Abstract
Epimedii Folium (EF, Epimedium brevicornu Maxim.), a traditional botanical drug, is famous for treating bone fractures, joint diseases, and several chronic illnesses. However, some studies indicated that EF could induce idiosyncratic drug-induced liver injury (IDILI) in the clinic. The NLRP3 inflammasome plays a crucial role in the pathogenesis of various human diseases, including IDILI. In the present study, we showed that epimedin B could specifically facilitate nigericin- or ATP-induced NLRP3 inflammasome activation under synergistic induction of mitochondrial reactive oxygen species. Moreover, epimedin B resulted in activation of Caspase-1 and IL-1β secretion in a lipopolysaccharide (LPS)-mediated susceptibility mouse model. MCC950 pretreatment completely abrogated activation of the NLRP3 inflammasome and prevented liver injury. Importantly, several studies have confirmed that some active constituents of EF could enhance activation of the NLRP3 inflammasome and may be involved in the pathogenesis of EF-IDILI. No reports are available on whether the structure-activity relationship associated with the immunostimulatory activity in EF contributes to the pathogenesis of EF-IDILI. These findings have changed our conventional understanding about the more glycogen, the more immunostimulatory activity.Keywords
Funding Information
- National Natural Science Foundation of China (82004057 81874368 82104522)
- Beijing Nova Program (Z181100006218001)
This publication has 32 references indexed in Scilit:
- Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical PerspectivesGastroenterology, 2014
- Acute Liver FailureNew England Journal of Medicine, 2013
- NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in miceHepatology, 2013
- IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in miceJournal of Clinical Investigation, 2012
- Inflammasomes in liver diseasesJournal of Hepatology, 2012
- A role for the NLRP3 inflammasome in metabolic diseases—did Warburg miss inflammation?Nature Immunology, 2012
- Hepatitis C virus activates interleukin-1β via caspase-1-inflammasome complexJournal of General Virology, 2012
- Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cellsHepatology, 2011
- The InflammasomesCell, 2010
- Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United StatesAnnals of Internal Medicine, 2002